Braveheart Bio, Inc.
BRVE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002131524
In the last 90 days, Braveheart Bio, Inc. insiders filed 9 open-market purchases and 0 sales; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Braveheart Bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 9 filings
- 9 insiders, $124.1M in total
- Open-market sells
- 0 filings
- Insiders trading
- 9
- Net value
- +$124.1M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Braveheart Bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Andreessen Marc L | 10% Owner | 10,232,420Indirect | Aug 11, 2026 | 1 |
| Horowitz Benjamin A | 10% Owner | 10,232,420Indirect | Aug 11, 2026 | 1 |
| AH Bio Fund IV, L.P. | 10% Owner | 10,232,420Indirect | Aug 11, 2026 | 1 |
| AH Equity Partners Bio IV, L.L.C. | 10% Owner | 10,232,420Indirect | Aug 11, 2026 | 1 |
| Chimovits Erez | Director, 10% Owner | 273,333Indirect | Aug 11, 2026 | 2 |
| OrbiMed Advisors LLC | Director, 10% Owner | 273,333Indirect | Aug 11, 2026 | 1 |
| OrbiMed Genesis GP LLC | Director, 10% Owner | 273,333Indirect | Aug 11, 2026 | 1 |
| OrbiMed Capital GP IX LLC | Director, 10% Owner | 273,333Indirect | Aug 11, 2026 | 1 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% Owner | 7,420,091 | Aug 10, 2026 | 1 |
| Forbion Growth III Management B.V. | 10% Owner | 10,185,478Indirect | Aug 7, 2026 | 1 |
| Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% Owner | 10,185,478Indirect | Aug 7, 2026 | 1 |
| Forbion Ventures Fund VII Cooperatief U.A. | 10% Owner | 10,185,478Indirect | Aug 7, 2026 | 1 |
| Forbion Ventures VII Management B.V. | 10% Owner | 10,185,478Indirect | Aug 7, 2026 | 1 |
| Rickey James Paul | Chief Financial Officer | 520,927 | Aug 7, 2026 | 1 |
| Lohoff Tim | Director | – | Aug 7, 2026 | 1 |
| Viehbacher Christopher | Director | 609,519 | Aug 7, 2026 | 1 |
| Malek David I | Director | 533,845 | Aug 7, 2026 | 1 |
| Anderson Michele A. | Chief Development Officer | 332,161 | Aug 7, 2026 | 1 |
| Murdoch Travis | CEO and President | 2,940,670 | Aug 7, 2026 | 1 |
| Bos Jasper | Director | – | Aug 7, 2026 | 1 |
| Lubner David Charles | Director | 55,555 | Aug 7, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2026 (view filing)5:53 PM ET | Aug 7 | 4 days | Andreessen Marc L and 3 others10% Owner | PPurchase | +1.10M | $18.00 | +$19.8M | +12.0%10.2M after | |
| Aug 11, 2026 (view filing)5:31 PM ET | Aug 7 | 4 days | Chimovits ErezDirector, 10% Owner | PPurchase | +1.94M | $18.00 | +$34.9M | New position273.3K after | 2 lotsDuplicate filing |
| Aug 11, 2026 (view filing)5:27 PM ET | Aug 7 | 4 days | OrbiMed Advisors LLC and 2 othersDirector, 10% Owner | PPurchase | +1.94M | $18.00 | +$34.9M | New position273.3K after | 2 lots |
| Aug 7, 2026 (view filing)5:25 PM ET | Aug 7 | Same day | Forbion Growth III Management B.V. and 3 others10% Owner | PPurchase | +1.92M | $18.00 | +$34.6M | +19.8%11.6M after | |
| Aug 7, 2026 (view filing)5:25 PM ET | Aug 7 | Same day | Forbion Growth III Management B.V. and 3 others10% Owner | PPurchase | +1.68M | $18.00 | +$30.2M | +19.8%10.2M after | |
| Aug 7, 2026 (view filing)4:41 PM ET | Aug 7 | Same day | Rickey James PaulChief Financial Officer | PPurchase | +27.8K | $18.00 | +$500.0K | +5.6%520.9K after | |
| Aug 7, 2026 (view filing)4:31 PM ET | Aug 7 | Same day | Viehbacher ChristopherDirector | PPurchase | +83.3K | $18.00 | +$1.50M | +15.8%609.5K after | |
| Aug 7, 2026 (view filing)4:31 PM ET | Aug 7 | Same day | Malek David IDirector | PPurchase | +4.17K | $18.00 | +$75.0K | +0.8%533.8K after | |
| Aug 7, 2026 (view filing)4:30 PM ET | Aug 7 | Same day | Anderson Michele A.Chief Development Officer | PPurchase | +1.11K | $18.00 | +$20.0K | +0.3%332.2K after | |
| Aug 7, 2026 (view filing)4:30 PM ET | Aug 7 | Same day | Murdoch TravisCEO and President | PPurchase | +83.3K | $18.00 | +$1.50M | +2.9%2.94M after | |
| Aug 7, 2026 (view filing)4:30 PM ET | Aug 7 | Same day | Lubner David CharlesDirector | PPurchase | +55.6K | $18.00 | +$1.00M | New position55.6K after |